ATE433752T1 - Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis - Google Patents

Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis

Info

Publication number
ATE433752T1
ATE433752T1 AT03027484T AT03027484T ATE433752T1 AT E433752 T1 ATE433752 T1 AT E433752T1 AT 03027484 T AT03027484 T AT 03027484T AT 03027484 T AT03027484 T AT 03027484T AT E433752 T1 ATE433752 T1 AT E433752T1
Authority
AT
Austria
Prior art keywords
compounds
benzodiazepine
benzodiazepines
atherosclerosis
viral infections
Prior art date
Application number
AT03027484T
Other languages
English (en)
Inventor
Gary Glick
Anthony Opipari
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE433752T1 publication Critical patent/ATE433752T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03027484T 1999-04-30 2000-04-27 Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis ATE433752T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13176199P 1999-04-30 1999-04-30
US16551199P 1999-11-15 1999-11-15
US19185500P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
ATE433752T1 true ATE433752T1 (de) 2009-07-15

Family

ID=27384197

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03027484T ATE433752T1 (de) 1999-04-30 2000-04-27 Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
AT00928586T ATE258439T1 (de) 1999-04-30 2000-04-27 Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00928586T ATE258439T1 (de) 1999-04-30 2000-04-27 Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen

Country Status (13)

Country Link
US (5) US7125866B1 (de)
EP (4) EP1398033B1 (de)
JP (1) JP5127096B2 (de)
AT (2) ATE433752T1 (de)
AU (2) AU782447C (de)
CA (1) CA2372150C (de)
DE (2) DE60007960T2 (de)
DK (1) DK1143946T3 (de)
ES (1) ES2214273T3 (de)
IL (2) IL146222A0 (de)
MX (1) MXPA01011052A (de)
PT (1) PT1143946E (de)
WO (1) WO2000066106A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785803B1 (fr) * 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2372150C (en) * 1999-04-30 2011-08-30 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
AU2002332560B2 (en) * 2001-08-15 2006-01-19 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
HRP20040415A2 (en) 2001-11-13 2005-04-30 3-Dimensional Pharmaceuticals Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
GB0221923D0 (en) * 2002-09-20 2002-10-30 Arrow Therapeutics Ltd Chemical compounds
PL375860A1 (en) 2002-09-20 2005-12-12 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
WO2005004988A2 (en) * 2003-05-01 2005-01-20 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP5172146B2 (ja) * 2003-05-09 2013-03-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 癌を標的化するための組成物及び方法
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
US20070293482A1 (en) * 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7581540B2 (en) 2004-08-12 2009-09-01 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2006203946B2 (en) 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1893218A4 (de) * 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
AU2006286441A1 (en) * 2005-09-02 2007-03-08 Janssen R&D Ireland Benzodiazepines as HCV inhibitors
US8039616B2 (en) 2005-09-19 2011-10-18 Astrazeneca Ab Benzodiazepine derivatives for treating hepatitis C infection
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) * 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
PL2001849T3 (pl) 2006-03-29 2015-04-30 Hoffmann La Roche Pochodne pirydyny i pirymidyny jako antagoniści mGluR2
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) * 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
US20100021928A1 (en) * 2006-06-26 2010-01-28 Technion Research & Development Foundation Ltd. Methods and kits for diagnosing cancer
CL2008000491A1 (es) * 2007-02-16 2008-08-22 Tibotec Pharm Ltd Compuestos derivados de 1,1-dioxo-1-tia-diaza-dibenzo ciclohepteno; composicion farmaceutica que comprende a dichos compuestos; proceso para la preparacion de dichos compuestos; y su uso para tratar la hepatitis c.
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
BRPI0808653A2 (pt) * 2007-03-09 2014-08-19 Univ Michigan Composições e métodos referindo-se a novos compostos e alvos dos mesmos.
CN101686983A (zh) * 2007-05-10 2010-03-31 Amr科技公司 芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途
ES2614498T3 (es) * 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
GB2456562A (en) * 2008-01-18 2009-07-22 Petra Technology Ltd Treatment of HIV/AIDS
EP2145873A1 (de) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Neue Verbindungen, die eine Schutzaktivität gegen die Wirkung von Toxinen und Viren über einen intrazellulären Wirkungsmechanismus entfalten
EP2352724B1 (de) 2008-09-11 2015-04-22 The Regents of the University of Michigan Arylguanidine-f1f0-aptase inhibitoren und deren therapeutischen verwendung
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US9075060B2 (en) 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
CN102190631B (zh) * 2010-03-10 2014-10-29 中国人民解放军63975部队 苯二氮卓化合物的制备方法
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
EP2897954B1 (de) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoralkyl-1,4-benzodiazepinon-verbindungen
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047391A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
EP2897946B1 (de) 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituierte bis(fluoralkyl)-1,4-benzodiazepinonverbindungen
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
EP2897960B1 (de) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclische/heterocyclische verbindungen als notch-inhibitoren
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CA2992839A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
EP3402799B1 (de) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclische verbindungen als rsv-inhibitoren
CN105693634B (zh) * 2016-03-17 2018-12-11 清华大学 化合物及其用途
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
WO2018129287A1 (en) * 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
JP7228588B2 (ja) 2017-11-13 2023-02-24 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン－２－オンおよびベンゾアゼピン－２－オン誘導体の分割方法
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
AU2020240024B2 (en) 2019-03-18 2025-06-26 Enanta Pharmaceuticals, Inc Benzodiazepine derivatives as RSV inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TWI864048B (zh) 2019-10-04 2024-12-01 美商安塔製藥公司 抗病毒雜環化合物、其醫藥組成物及其用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
GB202010409D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
JP2024507561A (ja) 2021-02-26 2024-02-20 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス複素環式化合物
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
CN117263873A (zh) * 2022-06-15 2023-12-22 复旦大学 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457405A (en) * 1945-09-25 1948-12-28 Monsanto Chemicals Halo nitroparaffin modified aminoplasts
DE1810423U (de) 1960-01-05 1960-04-28 Kaiserslautern Guss Armatur Schornsteinreinigungsverschluss.
US3374264A (en) * 1962-10-04 1968-03-19 Hoffmann La Roche N-haloacetyl-anthranilic acids and esters
US3261828A (en) 1962-10-04 1966-07-19 Hoffmann La Roche 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds
FR1497456A (fr) * 1964-06-15 1967-10-13 Clin Byla Ets Ortho-amino aryl cétimines, composés hétérocycliques qui s'y rattachent et prépaation de ces divers corps
NO120269B (de) * 1965-11-02 1970-09-28 Hoffmann La Roche
US3384635A (en) 1966-09-28 1968-05-21 Sterling Drug Inc 1, 4-benzodiazepine derivatives
US3415814A (en) 1966-09-28 1968-12-10 Sterling Drug Inc 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione
AT280290B (de) 1967-11-24 1970-04-10 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen
US4108852A (en) * 1969-03-18 1978-08-22 Knoll Ag. Process for preparing 1,5-benzodiazepine-2-ones
USRE30293E (en) * 1969-03-18 1980-06-03 Knoll A.G. Process for preparing 1,5-benzodiazepine-2-ones
GB1363735A (en) 1970-10-23 1974-08-14 Hoechst Ag Process for the manufacture of benzimidazolones
GB1324469A (en) * 1970-10-28 1973-07-25 Knoll Ag Derivatives of benzodiazepines
US3806594A (en) * 1972-11-24 1974-04-23 Abbott Lab Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium
ZA7468B (en) * 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferatave skin diseases with phosphodiesterase inhibitors
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US4110327A (en) * 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4076823A (en) 1977-08-18 1978-02-28 E. R. Squibb & Sons, Inc. Triazolo-2,4-benzodiazepines
JPS59112984A (ja) * 1982-12-21 1984-06-29 Shionogi & Co Ltd １，４−ベンゾジアゼピン誘導体
US4495101A (en) 1983-04-28 1985-01-22 American Home Products Corporation Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives
US4551480A (en) * 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
DE3435974A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
FR2591596B1 (fr) 1985-12-13 1988-09-09 Roussel Uclaf Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4751223A (en) 1986-10-14 1988-06-14 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US5147872A (en) * 1987-06-09 1992-09-15 Golwyn Daniel H Treatment of immunologically based disorders, specifically psoriasis
US4970207A (en) 1988-07-07 1990-11-13 Fujisawa Pharmaceutical Company, Ltd. Benzodiazepine derivatives
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5041438A (en) 1989-10-30 1991-08-20 Hoffmann-La Roche Inc. Method for treating retroviral infections with benzodiazepine compounds
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
EP0470246B1 (de) 1990-02-28 1995-06-28 Medtronic, Inc. Intraluminale prothese mit wirkstoffeluierung
DE69123090D1 (de) * 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
GB9015879D0 (en) * 1990-07-19 1990-09-05 Fujisawa Pharmaceutical Co Benzodiazepine derivatives
BR9200951A (pt) * 1991-03-21 1992-11-17 Hoffmann La Roche Compostos, processo para sua producao,preparacoes farmaceuticas e uso
US5597915A (en) 1992-03-16 1997-01-28 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives, compositions containing them and their use in therapy
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
AU692916B2 (en) * 1993-11-22 1998-06-18 Merck & Co., Inc. N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4- benzodiazepines
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5444092A (en) * 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
EP0804425A2 (de) * 1994-07-29 1997-11-05 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US5692337A (en) * 1995-06-07 1997-12-02 Motz, Jr.; Ronald W. Collapsible plant shelter
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5962337A (en) 1995-06-29 1999-10-05 Pharmacopeia, Inc. Combinatorial 1,4-benzodiazepin-2,5-dione library
RU2096044C1 (ru) 1995-07-19 1997-11-20 Малое предприятие "Ветта" Ветеринарный имплантируемый препарат для регулирования биологического ритма животных
US5776946A (en) 1995-08-28 1998-07-07 Mcgeer; Patrick L. Peripheral benzodiazepine receptor ligands as antiinflammatory agents
WO1997007828A1 (en) 1995-08-30 1997-03-06 The Regents Of The University Of California Therapy for cellular accumulation in chronic inflammatory diseases
KR100484294B1 (ko) * 1995-09-21 2005-09-09 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 레티노이드작용증강성화합물
US6579854B1 (en) * 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
ATE248823T1 (de) * 1996-12-10 2003-09-15 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
US6074859A (en) * 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
FR2772271B1 (fr) * 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
WO1999058117A1 (fr) 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
FR2785803B1 (fr) 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
US7175953B2 (en) * 1999-04-09 2007-02-13 Institute Fuer Diagnostik Forschung Short-warp peptide-dye conjugate as contrast agent for optical diagnostic
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
CA2372150C (en) * 1999-04-30 2011-08-30 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
US6524623B1 (en) * 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
AU2001255709A1 (en) * 2000-05-11 2001-11-20 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
CA2432825A1 (en) 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
NZ529582A (en) * 2001-06-07 2006-10-27 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2002332560B2 (en) 2001-08-15 2006-01-19 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
WO2003050261A2 (en) * 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7150433B2 (en) * 2002-08-16 2006-12-19 Toyota Motor Sales, U.S.A., Inc. Aircraft bolster trays
US20040087489A1 (en) * 2002-11-06 2004-05-06 Antonio Ruiz Compositions and methods for the treatment of mycobacterial infections
WO2004043362A2 (en) * 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Acyl guanidine compounds and use thereof
MXPA05005895A (es) * 2002-12-03 2006-02-08 Vela Pharmaceuticals Inc Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
CA2508914A1 (en) 2002-12-04 2004-06-17 Gene Logic Inc. Modulators of melanocortin receptor
WO2005004988A2 (en) 2003-05-01 2005-01-20 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7351241B2 (en) * 2003-06-02 2008-04-01 Carl Zeiss Meditec Ag Method and apparatus for precision working of material
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
TW200612948A (en) 2004-07-01 2006-05-01 Synta Pharmaceuticals Corp 2-substituted heteroaryl compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2006203946B2 (en) 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1893218A4 (de) * 2005-06-01 2011-01-12 Univ Michigan Ungelöste benzodiazepin-zusammensetzungen und verfahren
AU2006306347A1 (en) 2005-10-26 2007-05-03 The Regents Of The University Of Michigan Therapeutic compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
MX2008015488A (es) 2006-06-09 2009-02-12 Univ Michigan Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos.
BRPI0808653A2 (pt) 2007-03-09 2014-08-19 Univ Michigan Composições e métodos referindo-se a novos compostos e alvos dos mesmos.
ES2614498T3 (es) 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions

Also Published As

Publication number Publication date
DE60007960T2 (de) 2004-10-21
EP1143946A2 (de) 2001-10-17
PT1143946E (pt) 2004-05-31
US7220739B2 (en) 2007-05-22
DK1143946T3 (da) 2004-06-07
US20070036854A1 (en) 2007-02-15
EP2359831A2 (de) 2011-08-24
EP1398033A2 (de) 2004-03-17
WO2000066106A3 (en) 2001-08-16
JP2002543121A (ja) 2002-12-17
JP5127096B2 (ja) 2013-01-23
EP1143946B1 (de) 2004-01-28
IL146222A0 (en) 2002-07-25
US20090012065A1 (en) 2009-01-08
AU782447C (en) 2006-07-13
MXPA01011052A (es) 2002-11-22
US20140038947A1 (en) 2014-02-06
US20010016583A1 (en) 2001-08-23
EP1398033A3 (de) 2004-06-30
US7125866B1 (en) 2006-10-24
AU2005227385C1 (en) 2009-05-21
CA2372150A1 (en) 2000-11-09
AU2005227385A1 (en) 2005-12-01
ATE258439T1 (de) 2004-02-15
EP2062583B1 (de) 2012-12-26
CA2372150C (en) 2011-08-30
AU4680200A (en) 2000-11-17
EP2359831A3 (de) 2012-02-01
EP2062583A3 (de) 2009-12-30
DE60042425D1 (de) 2009-07-30
AU782447B2 (en) 2005-07-28
AU2005227385B2 (en) 2008-12-11
US8809323B2 (en) 2014-08-19
ES2214273T3 (es) 2004-09-16
WO2000066106A9 (en) 2002-04-18
IL146222A (en) 2008-06-05
DE60007960D1 (de) 2004-03-04
EP1398033B1 (de) 2009-06-17
EP2062583A2 (de) 2009-05-27
WO2000066106A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
ATE433752T1 (de) Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
ATE208777T1 (de) (a)-annelierte pyrrolderivate und deren anwendung in der pharmazie
DE69600985D1 (de) Substituierte Dihydrobenzo(b,f)Azepine, Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung von Erkrankungen des Zentralnervensystems und sie enthaltende pharmazeutische Zusammensetzungen
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
NO306977B1 (no) Anvendelse av tienol[1,5]benzodiazepin for behandling av tilstander i mave/tarmkanalen
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE296116T1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
CA2326970A1 (en) Acetylene derivatives as anti-inflammatory/analgesic agents
ATE223917T1 (de) (a)-annelierte pyrrolderivate und deren anwendung in der pharmazie
PT628033E (pt) Derivados de benzodiazepina uteis como antagonistas dos receptores-cck
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
EE03771B1 (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
TR200003122T2 (tr) Aril bağlı azapolisiklik bileşikler
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69329654D1 (de) 3-oxo-pyrido [1,2-a] benzimidazol-4-carboxyl und 4-oxo-azepino [1,2-a] benzimidazol-5-carboxyl derivate geeignet für die behandlung von zentralnervensystemerkrankungen
DE69824195D1 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
ATE306483T1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
ATE28647T1 (de) Chinazolinonderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis
DE69719190D1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung
ATE207923T1 (de) 5h, 10h-imidazo (1,2-a) indeno (1,2-e) pyrazin -4-one derivate ihre herstellung und diese enthaltende arzneimittel
BR0010748A (pt) Compostos heterocìclicos contendo imidazo, suas composições e usos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties